AI Getting Better at Detecting Skin Cancer
By Lori Solomon HealthDay Reporter
FRIDAY, Nov. 3, 2023 -- Artificial intelligence (AI) is increasingly accurate in detecting skin cancer, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Oct. 11 to 14 in Berlin.
Kashini Andrew, M.B.B.S., from the University Hospitals Birmingham NHS Foundation Trust in the United Kingdom, and colleagues examined improvement in the sensitivity of the detection of skin cancers with continued improvement of the AI algorithm (upgraded twice since May 2020) using previously collected data (22,356 patients assessed over 2.6 years).
The researchers found that the latest version of AI software was highly sensitive in detecting all skin cancers (99.5 percent), precancers (92.5 percent), and melanoma (100 percent), with improved sensitivity observed over time. Out of 190 cancers, AI missed one cancer diagnosis -- a basal cell carcinoma identified at the second read by the safety-net dermatologist. The latest algorithm also showed a high specificity in identifying benign lesions (75.3 percent). Compared with version 1, the researchers note a slight drop in specificity for benign lesions, a potential trade-off for increased sensitivity for malignant lesions. The rate of overturn of the diagnosis from benign to skin cancer was 0.1 percent, which was a significant improvement from version 1. The investigators estimated that the latest version prevented more than 2,000 face-to-face appointments in secondary care.
"The role of AI in dermatology and the most appropriate pathway are debated," Andrew said in a statement. "Further research with appropriate clinical oversight may allow the deployment of AI as a triage tool. However, any pathway must demonstrate cost-effectiveness, and AI is currently not a standalone tool in dermatology. Our data shows the great promise of AI in future provision of health care."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Non-Hispanic Black Melanoma Patients Present With Advanced Disease
WEDNESDAY, May 15, 2024 -- Non-Hispanic Black (NHB) melanoma patients have distinct tumor characteristics, presenting with more advanced disease and exhibiting worse outcomes...
Delayed Melanoma Care During Pandemic Proved Costly
TUESDAY, Feb. 27, 2024 -- Delays in melanoma diagnoses due to COVID-19 pandemic lockdowns were associated with a significant burden, including years of life lost and costs...
Amtagvi Approved by the FDA for Treatment of Advanced Melanoma
TUESDAY, Feb. 20, 2024 -- Amtagvi (lifileucel) has been approved by the U.S. Food and Drug Administration for the treatment of advanced melanoma. Amtagvi becomes the first...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.